454 related articles for article (PubMed ID: 26253728)
1. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
Thomas MC; Woodward M; Neal B; Li Q; Pickering R; Marre M; Williams B; Perkovic V; Cooper ME; Zoungas S; Chalmers J; Hillis GS;
Diabetes Care; 2015 Oct; 38(10):1891-7. PubMed ID: 26253728
[TBL] [Abstract][Full Text] [Related]
2. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
3. RAGE: a novel target for drug intervention in diabetic vascular disease.
Hudson BI; Schmidt AM
Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
[TBL] [Abstract][Full Text] [Related]
5. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.
Wadén JM; Dahlström EH; Elonen N; Thorn LM; Wadén J; Sandholm N; Forsblom C; Groop PH;
Diabetologia; 2019 Jul; 62(7):1268-1274. PubMed ID: 31127314
[TBL] [Abstract][Full Text] [Related]
6. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
Diabetes; 2010 Aug; 59(8):2027-32. PubMed ID: 20522598
[TBL] [Abstract][Full Text] [Related]
7. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
8. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
9. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
10. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
[TBL] [Abstract][Full Text] [Related]
11. RAGE in diabetic nephropathy.
Yamamoto H; Watanabe T; Yamamoto Y; Yonekura H; Munesue S; Harashima A; Ooe K; Hossain S; Saito H; Murakami N
Curr Mol Med; 2007 Dec; 7(8):752-7. PubMed ID: 18331233
[TBL] [Abstract][Full Text] [Related]
12. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
Bierhaus A; Ritz E; Nawroth PP
Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
14. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
Abdel-Azeez HA; El-Okely AM
Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
[TBL] [Abstract][Full Text] [Related]
15. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
[TBL] [Abstract][Full Text] [Related]
16. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
Melin EO; Dereke J; Hillman M
Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
[TBL] [Abstract][Full Text] [Related]
17. Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-β1 expression in mesangial cells under diabetic conditions.
Kim YS; Jung DH; Lee IS; Pyun BJ; Kim JS
Phytomedicine; 2016 Apr; 23(4):388-97. PubMed ID: 27002409
[TBL] [Abstract][Full Text] [Related]
18. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
Jandeleit-Dahm KA; Lassila M; Allen TJ
Ann N Y Acad Sci; 2005 Jun; 1043():759-66. PubMed ID: 16037303
[TBL] [Abstract][Full Text] [Related]
19. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
[TBL] [Abstract][Full Text] [Related]
20. DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice.
Sotokawauchi A; Matsui T; Higashimoto Y; Nishino Y; Koga Y; Yagi M; Yamagishi SI
Diab Vasc Dis Res; 2021; 18(1):1479164121990533. PubMed ID: 33535822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]